Signal Bioscience unveiled a chemistry that decouples amplification from signal generation to drive higher multiplexing in dPCR and qPCR while lowering costs, the startup said in an interview. Founded in 2023 in Ann Arbor, Michigan, the company demonstrated digital PCR multiplexing for up to 15 targets and aims for as many as 50 per reaction by pooling fluorophores in a secondary isothermal readout. CEO John Cunningham and CTO Vladimir Makarov are seeking seed funding and clinical or commercial collaborators to adapt the approach to syndromic infectious‑disease panels and oncology mutation profiling.